Latest Ratios: P/E Ratio 11.7x · EV/EBITDA 9.3x · ROE 10.2%. (2001–2026 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.2B | $2.9B | $4.3B | $3.6B | $3.1B | $2.7B | $2.2B | $1.9B | $1.6B | $1.8B | $3.0B |
| Enterprise Value | $3.2B | $3.9B | $5.3B | $4.7B | $4.4B | $4.2B | $3.7B | $3.5B | $3.3B | $3.8B | $5.1B |
| P/E Ratio → | 11.74 | 15.16 | 20.04 | 17.40 | — | 13.10 | 13.56 | 13.19 | — | 5.32 | 42.74 |
| P/S Ratio | 2.00 | 2.65 | 3.78 | 3.24 | 2.77 | 2.48 | 2.36 | 1.95 | 1.60 | 1.73 | 3.36 |
| P/B Ratio | 1.19 | 1.53 | 2.35 | 2.20 | 2.16 | 1.71 | 1.64 | 1.60 | 1.42 | 1.53 | 3.60 |
| P/FCF | 8.56 | 11.36 | 17.70 | 15.21 | 14.08 | 10.75 | 10.45 | 9.26 | 8.71 | 9.14 | 20.48 |
| P/OCF | 8.20 | 10.88 | 17.12 | 14.63 | 13.60 | 10.36 | 9.47 | 8.64 | 8.23 | 8.59 | 20.06 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.55 | 4.62 | 4.21 | 3.93 | 3.84 | 3.94 | 3.68 | 3.41 | 3.62 | 5.80 |
| EV / EBITDA | 9.27 | 11.36 | 14.31 | 12.69 | 434.20 | 11.52 | 11.34 | 10.79 | 33.52 | 15.10 | 22.11 |
| EV / EBIT | 10.20 | 12.90 | 15.83 | 13.79 | — | 12.76 | 12.96 | 12.33 | 49.66 | 11.68 | 25.03 |
| EV / FCF | — | 15.22 | 21.59 | 19.78 | 19.98 | 16.66 | 17.40 | 17.51 | 18.61 | 19.06 | 35.34 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 52.8% | 52.8% | 55.8% | 55.5% | 55.4% | 57.1% | 58.0% | 57.3% | 56.9% | 55.4% | 56.7% |
| Operating Margin | 28.4% | 28.4% | 29.6% | 30.4% | -2.0% | 30.4% | 31.5% | 30.2% | 6.9% | 20.7% | 23.3% |
| Net Profit Margin | 17.5% | 17.5% | 18.9% | 18.6% | -7.3% | 18.9% | 17.5% | 14.8% | -3.7% | 32.6% | 7.9% |
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 10.2% | 10.2% | 12.3% | 13.5% | -5.4% | 14.0% | 13.0% | 12.6% | -3.1% | 33.9% | 8.9% |
| ROA | 5.5% | 5.5% | 6.4% | 6.3% | -2.3% | 5.8% | 4.7% | 4.1% | -1.0% | 8.9% | 2.0% |
| ROIC | 8.2% | 8.2% | 9.1% | 9.3% | -0.6% | 8.4% | 7.8% | 7.6% | 1.7% | 5.3% | 5.8% |
| ROCE | 9.2% | 9.2% | 10.4% | 10.7% | -0.7% | 9.7% | 8.9% | 8.7% | 1.9% | 5.8% | 6.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.55 | 0.55 | 0.57 | 0.69 | 0.94 | 0.95 | 1.12 | 1.51 | 1.64 | 1.69 | 2.67 |
| Debt / EBITDA | 3.07 | 3.07 | 2.85 | 3.05 | 133.90 | 4.16 | 4.62 | 5.37 | 18.12 | 7.99 | 9.48 |
| Net Debt / Equity | — | 0.52 | 0.52 | 0.66 | 0.90 | 0.94 | 1.09 | 1.43 | 1.62 | 1.66 | 2.62 |
| Net Debt / EBITDA | 2.88 | 2.88 | 2.58 | 2.93 | 128.17 | 4.09 | 4.53 | 5.08 | 17.84 | 7.86 | 9.30 |
| Debt / FCF | — | 3.86 | 3.89 | 4.57 | 5.90 | 5.91 | 6.95 | 8.25 | 9.91 | 9.92 | 14.86 |
| Interest Coverage | 7.08 | 7.08 | 6.97 | 5.11 | -0.36 | 5.08 | 3.48 | 2.98 | 0.64 | 3.03 | 2.18 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.57 | 3.57 | 4.20 | 3.20 | 2.44 | 2.04 | 2.21 | 2.44 | 2.37 | 2.46 | 2.06 |
| Quick Ratio | 2.25 | 2.25 | 2.82 | 2.02 | 1.43 | 1.21 | 1.27 | 1.67 | 1.43 | 1.50 | 1.35 |
| Cash Ratio | 0.53 | 0.53 | 0.92 | 0.40 | 0.36 | 0.19 | 0.26 | 0.63 | 0.22 | 0.26 | 0.26 |
| Asset Turnover | — | 0.31 | 0.33 | 0.34 | 0.34 | 0.30 | 0.28 | 0.27 | 0.28 | 0.28 | 0.23 |
| Inventory Turnover | 3.23 | 3.23 | 3.41 | 3.61 | 3.10 | 3.87 | 3.44 | 3.54 | 3.51 | 3.92 | 3.30 |
| Days Sales Outstanding | — | 64.34 | 62.33 | 57.34 | 54.06 | 46.79 | 44.37 | 57.05 | 55.66 | 49.39 | 56.58 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 8.5% | 6.6% | 5.0% | 5.7% | — | 7.6% | 7.4% | 7.6% | — | 18.8% | 2.3% |
| FCF Yield | 11.7% | 8.8% | 5.7% | 6.6% | 7.1% | 9.3% | 9.6% | 10.8% | 11.5% | 10.9% | 4.9% |
| Buyback Yield | 7.2% | 5.4% | 1.2% | 0.7% | 1.6% | 0.0% | 0.5% | 3.0% | 3.2% | 0.1% | 0.0% |
| Total Shareholder Yield | 7.2% | 5.4% | 1.2% | 0.7% | 1.6% | 0.0% | 0.5% | 3.0% | 3.2% | 0.1% | 0.0% |
| Shares Outstanding | — | $49M | $50M | $50M | $50M | $51M | $51M | $51M | $52M | $54M | $53M |
Includes 30+ ratios · 26 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PBH stock.
Prestige Consumer Healthcare Inc.'s current P/E ratio is 11.7x. The historical average is 19.3x. This places it at the 6th percentile of its historical range.
Prestige Consumer Healthcare Inc.'s current EV/EBITDA is 9.3x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 13.7x.
Prestige Consumer Healthcare Inc.'s return on equity (ROE) is 10.2%. The historical average is 6.0%.
Based on historical data, Prestige Consumer Healthcare Inc. is trading at a P/E of 11.7x. This is at the 6th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Prestige Consumer Healthcare Inc. has 52.8% gross margin and 28.4% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Prestige Consumer Healthcare Inc.'s Debt/EBITDA ratio is 3.1x, indicating high leverage. A ratio between 2-4x is manageable but warrants monitoring.
Key Metrics
Top Statement Risk
Acquisition-driven leverage spike
Metrics are mathematically derived from official filings.
Discounted Multiple, Uncertain Growth
PBH trades at 13.1x trailing earnings and 10.0x EV/EBITDA, a discount to Kenvue's 25.3x and Haleon's 19.9x, per peer data, implying the market prices in limited organic growth.
The forward P/E of 11.3x suggests the market expects earnings growth, but the PEG of 3.49 indicates that the growth embedded in the multiple is modest relative to the broader market. The EV/EBITDA of 10.0x is below the peer median, reflecting skepticism about the sustainability of recent margin compression. Given the recent revenue decline and the acquisition-driven leverage increase, the discount appears justified unless organic growth reaccelerates.
Margin Compression Pressures Earnings Power
Gross margin fell from 59.2% in 2025Q4 to 51.3% in 2027Q1, while operating margin dropped from 29.8% to 19.8%, according to reported figures, suggesting cost pressures and negative operating leverage.
The 800 basis point gross margin decline over five quarters is significant and may reflect higher input costs or a shift in product mix. Operating margin compression was even steeper, driven by a 19% year-over-year increase in SG&A, which outpaced the 6.5% revenue growth. This indicates that the company's cost structure is becoming less flexible, and the recent EPS miss may be a symptom of this trend. Investors should monitor whether management can restore margins through pricing or cost discipline.
ROIC Decay on Acquisition Splurge
ROIC fell to 1.2% in 2027Q1 from 2.4% in 2025Q4, per financial statements, as the $1.0B acquisition expanded the capital base faster than operating income, diluting returns.
The decline in ROIC is a direct consequence of the acquisition, which added debt and intangibles without an immediate corresponding increase in earnings. The company's ROE also dropped to 1.5% from 2.8% over the same period, indicating that the acquisition has not yet generated sufficient returns to cover its cost of capital. This suggests that management's capital allocation may be value-destructive in the near term, and the market's discount may be warranted until integration benefits materialize.
Working Capital Drag Intensifies
Cash conversion cycle lengthened to 167 days in 2027Q1 from 134 days in 2024Q4, as DSO rose to 65 days and DIO to 123 days, based on reported data, indicating slower cash recovery.
The increase in DSO and DIO suggests that PBH is taking longer to collect receivables and turn over inventory, which may be due to retailer inventory adjustments or slower-moving product lines. DPO remained low at 21 days, indicating limited supplier leverage. The extended CCC ties up cash and may pressure liquidity, especially given the recent debt-funded acquisition. This trend warrants monitoring as it could signal weakening demand or channel stuffing.
Leverage Doubles on Acquisition
Debt-to-equity surged to 1.08 in 2027Q1 from 0.55 in 2026Q4, and D/EBITDA jumped to 33.7x, per balance sheet data, reflecting the $1.0B acquisition and raising refinancing risk.
The dramatic increase in leverage is a red flag, as interest coverage fell to 3.76x from 6.67x, indicating thinner coverage of interest expenses. The D/EBITDA of 33.7x is exceptionally high, though this may be distorted by the timing of the acquisition and the recent EBITDA decline. If the company cannot generate sufficient cash flow to service this debt, it may face covenant pressure or be forced to divest assets. Investors should closely monitor the integration progress and debt repayment plans.
Liquidity Cushion Thins
Current ratio remains healthy at 3.23 in 2027Q1, but cash dropped to $89.1M from $63.9M, per reported figures, and the quick ratio fell to 1.99, indicating reduced short-term flexibility.
While the current ratio is still above 3, the decline in cash and the increase in inventory days suggest that liquidity is being consumed by working capital needs. The quick ratio of 1.99 is still comfortable, but the trend is concerning. The company's ability to weather a severe downturn or unexpected cash needs may be constrained, especially with elevated debt levels. The $1.0B acquisition likely consumed a significant portion of cash reserves, leaving less buffer for operational hiccups.
Valuation Discount vs. Peers
PBH's P/E of 13.1x and EV/EBITDA of 10.0x are below Kenvue's 25.3x and Haleon's 19.9x, per peer data, reflecting its smaller scale and higher leverage.
The discount to larger OTC peers may be justified by PBH's slower organic growth and recent margin pressure. However, its ROE of 1.5% is far below Church & Dwight's 17.8% and Haleon's 19.4%, indicating lower profitability on equity. The company's asset-light model and high FCF margin (25.2% in 2027Q1) are positives, but the market appears to be pricing in execution risk. If PBH can stabilize revenue and integrate the acquisition successfully, the valuation gap could narrow.
Misapplied P/E on Acquired Intangibles
The P/E ratio is commonly misapplied to PBH because GAAP earnings are depressed by amortization of acquired intangibles, which are non-cash and not indicative of economic earnings, per accounting standards.
PBH's business model relies on acquisitions, leading to significant intangible amortization that reduces reported net income. As a result, the P/E ratio overstates the company's true earnings power. Investors should instead focus on cash-based metrics like P/FCF (9.57x) or EV/EBITDA (10.03x), which exclude non-cash charges. Additionally, adjusting for amortization and one-time items would provide a clearer picture of underlying profitability. The market's reliance on P/E may lead to an undervaluation of PBH's cash-generative assets.